

House Bill 2692

Sponsored by Representative NOSSE; Representatives ALONSO LEON, SANCHEZ (Pre-session filed.)

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure **as introduced**.

Requires Pharmacy and Therapeutics Committee to publish on website of Oregon Health Authority within seven days recommendations concerning Practitioner-Managed Prescription Drug Plan. Requires Director of the Oregon Health Authority to make decision to approve, disapprove or modify committee's recommendation as soon as practicable and publish decision on website.

Requires decision of director to be implemented no later than seven days after decision is published on website. Interested persons may request reconsideration of director's approval of recommendation no later than seven days after director's determination is published on website. Director may immediately implement recommendation or delay recommendation based on specified conditions.

Declares emergency, effective on passage.

A BILL FOR AN ACT

1
2 Relating to the Practitioner-Managed Prescription Drug Plan; creating new provisions; amending
3 ORS 414.361; and declaring an emergency.

4 **Be It Enacted by the People of the State of Oregon:**

5 **SECTION 1.** ORS 414.361 is amended to read:

6 414.361. (1) The Pharmacy and Therapeutics Committee shall advise the Oregon Health Author-
7 ity on:

8 (a) Adoption of rules to implement ORS 414.351 to 414.414 in accordance with ORS chapter 183.

9 (b) Implementation of the medical assistance program retrospective and prospective programs
10 as described in ORS 414.351 to 414.414, including the type of software programs to be used by the
11 pharmacist for prospective drug use review and the provisions of the contractual agreement between
12 the state and any entity involved in the retrospective program.

13 (c) Development of and application of the criteria and standards to be used in retrospective and
14 prospective drug use review in a manner that ensures that such criteria and standards are based
15 on compendia, relevant guidelines obtained from professional groups through consensus-driven pro-
16 cesses, the experience of practitioners with expertise in drug therapy, data and experience obtained
17 from drug utilization review program operations. The committee shall have an open professional
18 consensus process for establishing and revising criteria and standards. Criteria and standards shall
19 be available to the public. In developing recommendations for criteria and standards, the committee
20 shall establish an explicit ongoing process for soliciting and considering input from interested par-
21 ties. The committee shall make timely revisions to the criteria and standards based upon this input
22 in addition to revisions based upon scheduled review of the criteria and standards. Further, the drug
23 utilization review standards shall reflect the local practices of prescribers in order to monitor:

24 (A) Therapeutic appropriateness.

25 (B) Overutilization or underutilization.

26 (C) Therapeutic duplication.

27 (D) Drug-disease contraindications.

NOTE: Matter in **boldfaced** type in an amended section is new; matter [*italic and bracketed*] is existing law to be omitted. New sections are in **boldfaced** type.

1 (E) Drug-drug interactions.

2 (F) Incorrect drug dosage or drug treatment duration.

3 (G) Clinical abuse or misuse.

4 (H) Drug allergies.

5 (d) Development, selection and application of and assessment for interventions that are educa-
6 tional and not punitive in nature for medical assistance program prescribers, dispensers and pa-
7 tients.

8 (2) In reviewing retrospective and prospective drug use, the committee may consider only drugs
9 that have received final approval from the federal Food and Drug Administration.

10 (3) The committee shall make recommendations to the authority, subject to approval by the Di-
11 rector of the Oregon Health Authority or the director's designee, for drugs to be included on any
12 preferred drug list adopted by the authority and on the Practitioner-Managed Prescription Drug
13 Plan. The committee shall also recommend all utilization controls, prior authorization requirements
14 or other conditions for the inclusion of a drug on a preferred drug list.

15 (4) In making recommendations under subsection (3) of this section, the committee may use any
16 information the committee deems appropriate. The recommendations must be based upon the fol-
17 lowing factors in order of priority:

18 (a) Safety and efficacy of the drug.

19 (b) The ability of Oregonians to access effective prescription drugs that are appropriate for their
20 clinical conditions.

21 (c) Substantial differences in the costs of drugs within the same therapeutic class.

22 *[(5) The committee shall post a recommendation to the website of the authority no later than 30*
23 *days after the date the committee approves the recommendation. The director shall approve, disapprove*
24 *or modify any recommendation of the committee as soon as practicable, shall publish the decision on*
25 *the website and shall notify persons who have requested notification of the decision. A recommendation*
26 *adopted by the director, in whole or in part, with respect to the inclusion of a drug on a preferred drug*
27 *list or the Practitioner-Managed Prescription Drug Plan may not become effective less than 60 days*
28 *after the date that the director's decision is published.]*

29 *[(6) The director shall reconsider any decision to adopt or modify a recommendation of the com-*
30 *mittee with respect to the inclusion of a particular drug on a preferred drug list or the Practitioner-*
31 *Managed Prescription Drug Plan, upon the request of any interested person filed no later than 30 days*
32 *after the director's decision is published on the website. The decision on reconsideration shall be sent*
33 *to the requester and posted to the website without undue delay.]*

34 **(5)(a) No later than seven days after the date on which the committee makes a recom-**
35 **mendation under subsection (3) of this section, the committee shall publish the recommen-**
36 **dation on the website of the authority.**

37 **(b) As soon as practicable after the committee makes a recommendation, the director**
38 **shall decide whether to approve, disapprove or modify the recommendation, shall publish the**
39 **decision on the website and shall notify persons who have requested notification of the de-**
40 **cision.**

41 **(c) Except as provided in subsection (6) of this section, a recommendation approved by**
42 **the director, in whole or in part, with respect to the inclusion of a drug on a preferred drug**
43 **list or the Practitioner-Managed Prescription Drug Plan may not become effective less than**
44 **seven days after the date that the director's decision is published on the website.**

45 **(6)(a) The director may allow the immediate implementation of a recommendation de-**

1 scribed in subsection (5)(c) of this section if the director determines that immediate imple-
2 mentation is necessary to protect patient safety or to comply with state or federal
3 requirements.

4 (b) The director shall reconsider any decision to approve, disapprove or modify a recom-
5 mendation described in subsection (5)(c) of this section upon the request of any interested
6 person filed no later than seven days after the director's decision is published on the website
7 of the authority. The director's determination regarding the request for reconsideration shall
8 be sent to the requester and posted to the website without undue delay. Upon receipt of a
9 request for reconsideration, the director may:

10 (A) Delay the implementation of the recommendation pending the reconsideration pro-
11 cess; or

12 (B) Implement the recommendation if the director determines that delay could reason-
13 ably result in harm to patient safety or would violate state or federal requirements.

14 SECTION 2. The amendments to ORS 414.361 by section 1 of this 2019 Act apply to rec-
15 ommendations by the Pharmacy and Therapeutics Committee under ORS 414.361 made on
16 or after the effective date of this 2019 Act.

17 SECTION 3. This 2019 Act being necessary for the immediate preservation of the public
18 peace, health and safety, an emergency is declared to exist, and this 2019 Act takes effect
19 on its passage.

20 _____